美洛昔康

měi luò xī kānɡ
  • Meloxicam
美洛昔康美洛昔康
  1. 吲哚美辛和美洛昔康对脂多糖诱导的小鼠腹腔巨噬细胞NF-κB的抑制作用

    Inhibitory effects of indomethacin and meloxicam on nf - κ b in mouse peritoneal macrophages

  2. HPLC法测定美洛昔康分散片的含量这些遗迹充分证明此处昔日的宏伟。

    Determination of Meloxicam Dispersible Tablets by HPLC These ruins sufficiently attest the former grandeur of the place .

  3. HPLC法测定血及组织中美洛昔康药物浓度

    Determination of Mel concentration in serum and local tissue by HPLC

  4. 预先给美洛昔康后LPS所致COX-2蛋白在大鼠脑内的表达

    Expression of LPS-induced Cyclooxygenase-2 Protein in the Rat Brain with Meloxicam Given Beforehand

  5. 美洛昔康凝胶治疗AA大鼠的疗效与局部药物浓度的关系研究

    The relationship between therapeutic effects and concentration in tissue or serum of Mel G

  6. 美洛昔康治疗类风湿关节炎与骨关节炎的疗效及安全性Meta分析

    Efficacy and Safety of Meloxicam for Rheumatoid Arthritis and Osteoarthritis : A Meta-analysis

  7. 美洛昔康在HCl底液中的单扫示波极谱法测定

    Single Sweep Oscillopolarography of Meloxicam in HCl Supporting Electrolyte

  8. RP-HPLC法测定美洛昔康片的含量

    Determination Method for Meloxicam Tablets by RP-HPLC

  9. 治疗组用美洛昔康15mg·d-1;

    The treated group was given with meloxicam 15 mg .

  10. 目的:评价国产美洛昔康片剂治疗类风湿关节炎(RA)和骨关节炎病人(OA)的临床疗效和不良反应。

    AIM : To evaluate the clinical efficacy and adverse reactions of domestic meloxicam tablet in the treatment of rheumatoid arthritis ( RA ) and osteoarthritis ( OA ) .

  11. 环氧合酶-2抑制剂美洛昔康对人膀胱癌T24细胞体内外生长的影响

    Influence of selective cyclooxygenase-2 inhibitor on growth of human bladder carcinoma

  12. 目的观察兔单次皮肤外用美洛昔康(meloxicam,Mel)凝胶的透皮吸收及药物在体内的动态过程,估算其药动学参数。

    AIM To study the course of percutaneous absorption and pharmacokinetics of meloxican ( Mel ) gel which used in skin of rabbit .

  13. 内毒素致兔急性肺损伤IL-19变化及美洛昔康的拮抗作用

    Changes in IL-19 and antagonizing effects of meloxicam on endotoxin-induced acute lung injury in rabbits

  14. 方法:以小鼠和大鼠为对象,将美洛昔康按灌胃和腹腔注射两种给药方式进行急性毒性试验,用Bliss法测得LD50及95%置信限。

    Method : The drug was administered to the rats and mice by ig and ip during the acute toxicity test , LD50 and 95 % confidence limit of the drug were determined by Bliss ' methods .

  15. 美洛昔康分散片(扬子江药业集团有限公司生产,国家准字号:H20010108)7.5mg/次,2次/天,饭后服。

    Meloxicam tablet ( Yangtze River Pharmaceutical Group Co. , Ltd. Production ) 7.5mg / times , 2 times / day , meal service .

  16. 结果ET致伤组IL-19含量显著高于对照组(P<0.01),美洛昔康干预组IL-19显著低于ET组(P<0.01)。

    Results IL-19 expression in ET challenged group was significantly higher than that in control group ( P < 0.01 ), while it was significantly lower in meloxicam treated group than that in ET challenged group ( P < 0.01 ) .

  17. 目的观察内毒素(ET)致兔急性肺损伤(ALI)模型肺组织白介素-19(IL-19)含量的变化,探讨ET致伤机制及美洛昔康的拮抗作用。

    Objective To investigate the changes in interleukin-19 ( IL-19 ) in lungs of rabbits with acute lung injury ( ALI ) induced by endotoxin ( ET ), so as to study the mechanism of injury of ET to the lung and the protective mechanism of meloxicam .

  18. 目的研究美洛昔康(meloxicam,简称MLX)的电化学行为和电极反应机理,拟定了测定MLX的吸附伏安法。

    AIM To study the electrochemical behavior and reduction mechanism of meloxicam ( MLX ) in acetate buffer solution . A new method for the determination of MLX was established by adsorptive stripping voltammetry .

  19. 美洛昔康凝胶剂对佐剂性关节炎大鼠的治疗作用

    The therapeutic effects of meloxicam gels on AA rats

  20. 不良反应发生率:美洛昔康为1053%;

    The incidence of adverse drug reaction of meloxicam were 10 53 % ;

  21. 美洛昔康对慢性铝过负荷致大鼠神经元退变的保护作用及机制

    Protective Effects and Mechanisms of Meloxicam on Chronic Aluminum Overload-Induced Neurodegeneration of Rats

  22. 美洛昔康致重症药疹、类白血病反应及肝炎

    Severe drug eruption , leukemoid reaction , and hepatitis in relation to meloxicam

  23. 催化氢波法测定美洛昔康

    Determination of meloxicam using polarographic catalytic hydrogen wave method

  24. 美洛昔康凝胶的透皮吸收及药代动力学研究

    The study of meloxicam gels percutaneous absorption and pharmacokinetics

  25. 大口径石英毛细管柱测定美洛昔康中残留溶剂的方法

    Determination of Residual Solvent in Meloxicam by Wide-bore Quartz Capillary Gas Chromatographic Column

  26. 应用线性扫描极谱法和循环伏安法对美洛昔康的极谱行为进行了研究。

    The voltammetric behavior of meloxicam was studied using linear scan voltammetry and cyclic voltammetry .

  27. 国产美洛昔康胶囊与进口莫比可片的生物等效性研究

    Bioequivalence Assessment of Domestic Capsule of Meloxicam

  28. 安全性评价:美洛昔康不良反应发生率:10.2%;萘丁美酮18.0%,统计分析两药的耐受性无明显差异。

    The incidence of adverse effects was 10.2 % for meloxicam and 18.0 % for nabumetone .

  29. 美洛昔康对大鼠致畸敏感期的毒性试验研究

    Teratologic Study on Meloxicam in Rats

  30. 驻极体美洛昔康贴剂储电性能及其药物透皮的在体动物实验研究

    Research of Electret Meloxicam Patch on the Charge Storage Properties and Drug Transdermal Enhancement in Vivo